Pfizer buys targeted cancer drug maker Seagen; how SVB's collapse rattled the biotech industry

Taking stock of the drug industry, from the lab to the medicine chest

March 13, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

ADOBE STAT+ | Veterans Health Administration will cover the newest Alzheimer's drug About 80% to 90% of veterans who clear coverage hurdles may be eligible for the treatment, according to Eisai. By Ed Silverman STAT+ | Pfizer buys Seagen, maker of targeted cancer drugs, for $43 billion The Seagan deal helps Pfizer, in need of new sources of revenue, by adding a lineup of cancer drugs called antibody-drug conjugates. By Adam Feuerstein STAT+ | French pharma Sanofi buys maker of diabetes treatment for $2.9 billion Sanofi said the acquisition will bolster the growth of its business targeting immune-mediated diseases and disease-modifying therapies. By Adam Feuerstein NOAH BERGER/AFP via Getty Images STAT+ | 102 hours of chaos: How SVB's collapse rattled the biotech industry The events of just a few days laid bare just how vulnerable the biotech and tech industries were to the financial turmoil at SVB. By Allison DeAngelis STAT+ | Illumina has been ignoring its investors, but it can't ignore Carl Icahn Icahn argues Illumina is playing a losing hand with its actions related to the pursuit of its merger with Grail. By Matthew Herper STAT+ | Biogen's Samantha Budd Haeberlein, an architect of Aduhelm, leaves company The Biogen executive's departure comes two weeks after FDA's Billy Dunn, whom she worked closely with on Aduhelm's review, left the agency. By Adam Feuerstein and Damian Garde

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser